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INTRODUCTION
Preclinical Alzheimer’s disease (Pre-AD) has been regarded as the preclinical pathological state of
mild cognitive impairment (MCI) and Alzheimer’s disease (AD; Sperling et al., 2011), and becomes
a popular research field currently. At present, many researchers studied the biomarkers of Pre-AD
from several angles, including of neuropsychology scales (Duara et al., 2011), structural Magnetic
Resonance Imaging (sMRI; Wang et al., 2013), functional Magnetic Resonance Imaging (fMRI;
Brier et al., 2014), Positron Emission Tomography (Doraiswamy et al., 2012), cerebrospinal fluid
(Moghekar et al., 2013), gene (Ferencz et al., 2012), and cognitive reserve (Soldan et al., 2015), and
then made a series of achievement. Considering of simpleness and shortcut of diagnosis, sMRI,
and fMRI as important biomarkers become the major inspection means of cerebral disease in
clinical tests increasingly. At present, many studies analyzed the biomarkers of Pre-AD in depth,
including of cerebral structure, brain functional connection, brain networks and their relationship
with gene and protein of Pre-AD from sMRI, and fMRI aspects (Brier et al., 2014; Besson et al.,
2015; Gordon et al., 2015; Miller et al., 2015; Harrison et al., 2016). However, these studies are still
in early stages, and many conclusions need to be further verified. In addition, the data processing
and analysis methods in these studies remain to be further explored, and there still exist many
unsolved problems.
Therefore, this paper will analyze in depth the literatures related to Pre-AD from the angles of
sMRI and fMRI, and propose our opinions. It is expected that the analysis can supply several ideas
for the researchers in Pre-AD diagnosis field.
THE ANALYSIS OF PRE-AD BASED ON sMRI
Changes of Brain Structure and Network via sMRI
Many studies related to the biomarkers of sMRI suggested that the atrophy of partial cerebral
regions was regarded as a visual display of Pre-AD, which can use to predict or diagnose Pre-
AD. Michael I. Miller et al. found that entorhinal cortex was the best sensitive brain region and
also brain structure which changed at the earliest stages during the process of AD, and had a
maximal atrophic rate in comparison with hippocampus and amygdala (Miller et al., 2015). Other
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studies also displayed that atrophic and mutation existed in
entorhinal cortex at first (Miller et al., 2013; Younes et al., 2014),
and the change was earlier than clinical manifestation about 8–
10 years (Younes et al., 2014; Miller et al., 2015). When the
change points across network were processed in the way of signal
processing, different atrophic rate of intermediate caudal subarea
of the entorhinal cortex would affect their own progress of signal
processing (Miller et al., 2015). This result suggested that the
nerve degeneration in Pre-AD presented a feature of selectivity.
Other relevant studies also suggested that variation of
hippocampus and related brain regions could be regarded as
the biomarkers. In 2015, Michael I. Miller et al. found that the
hippocampus and amygdala atrophy appeared even later than
entorhinal cortex, and the variation of amygdala appeared in
basolateral and lateral areas of amygdala firstly (Miller et al.,
2015). In addition, Laurent Younes et al. also found that the
hippocampus atrophy happened in about 2–4 years before the
clinical manifestation, and the amygdala atrophy also was earlier
than clinical manifestation about 3 years (Younes et al., 2014).
The study of Florent L Besson et al. suggested that volumes
of hippocampus, ventro-medial prefrontal, fronto-insular, and
lateral temporal cortex were less in sMRI-positive health elder
(HE) than sMRI-negative HE (Besson et al., 2015). Anja Soldan
et al. found that occurrence of the cognitive degeneration of Pre-
AD can be predicted by the significant variation on standard
volumes of right hippocampus and standard thickness of right
and bilateral entorhinal cortex, and for example, the decrease
of volume or thickness was related to the advanced clinical
symptom (Soldan et al., 2015).
In addition, the change of brain networks also an important
biomarker. Michael I. Miller et al. found that there existed
abnormal change on substructure junction of medial temporal
lobe (MTL) network of Pre-AD by analyzing high-field 11T
atlasing sMRI (Miller et al., 2015).
Changes of Relationship between Brain
Imaging via sMRI and Protein, Cognitive
Reserve, and Gene
A few studies used multiple biomarkers including of sMRI to
detect Pre-AD, and compared the performances of different
biomarkers. Protein is the first biomarker related to brain
imaging via sMRI. Florent L Besson et al. found that the volumes
and metabolism velocity from AD-characteristic regions and
prefrontal cortex of MRI-positive HE were decreased (Besson
et al., 2015). The study also displayed that Aβ deposition was
related to the appearance of Pre-AD symptom, and the insular,
frontal, and temporal areas of HE with sMRI-negative had more
Aβ deposition than HE with sMRI-positive (Besson et al., 2015).
Another biomarker is cognitive reserve (CR), which changed
the relationship with brain imaging via sMRI when symptom of
Pre-AD emerge. At the beginning of clinical symptom, CR values,
and sMRImeasures of hippocampus and amygdala volumes were
not relative significantly (Soldan et al., 2015). Accounting for
CR and ApoE genotype, the symptom of cognitive degeneration
would appear earlier when right entorhinal cortex thickness,
right and bilateral hippocampus volumes were smaller, which
is consistent with the simple baseline models (Soldan et al.,
2015). CR scores and baseline sMRI measures were significantly
correlated on bilateral and left volume of entorhinal cortex
(Soldan et al., 2015).
In addtion, gene is the last biomarker, which changed the
relationship with brain imaging. Anja Soldan et al. found that
only atrophy rate of left amygdala in the simple Cox regression
models was related to ApoE-E4 genotype, which was regarded as
a biomarker, when the clinical symptom was predicted (Soldan
et al., 2015). Furthermore, there existed a larger atrophy rate in
left amydala of ApoE-E4 genotype carrier relative to non-carrier,
which was related to the earlier emergence of clinical symptom,
and the relationship was not obvious on non-carrier (Soldan
et al., 2015).
Problems to be Solved in the Future
In the future, there exist three problems to be solved
preferentially. From a localization perspective, future sMRI
studies require to localize focal zones of Pre-AD precisely, which
contribute to diagnosis, interposition, and treatment of Pre-AD.
From a gene perspective, the correlation between Aβ deposition
and brain volumes of sMRI-negative or sMRI-positive, also the
relationship between ApoE-E4 genotype and the atrophy of
specific brain regions all need to be quantified, in order to help us
to directly diagnose Pre-AD via sMRI. From a CR perspective, we
need to explore the correlation between other cognitive measures
replacing CR and sMRI measures of left and bilateral volume of
entorhinal cortex, so as to verify the sensibility of these brain
regions in diagnosis of Pre-AD.
THE ANALYSIS OF PRE-AD BASED ON
fMRI
Changes of Brain Regions and Functional
Connection via fMRI
A few studies in biomarkers suggested that there existed
abnormities on function of brain regions and functional
connectivity between different brain regions of Pre-AD (Sheline
et al., 2010; Gordon et al., 2015; Harrison et al., 2016). Brian
A.Gordon et al. expressed the deactivations and activations of
Pre-AD brain regions by computing blood oxygen level via fMRI,
and detected the change of attentional networks triggered by
the task (Gordon et al., 2015). When the frequency of each
word increased, precuneus presented smaller deactivation. And
the activations of left dorsolateral prefrontal cortex increased
obviously when the frequency decreased (Gordon et al., 2015).
According to resting state fMRI study, Yvette I. Sheline found
that for the non-cognitive impairment elders with and without
amyloid plaques, the functional connectivity between precuneus
and hippocampus, parahippocampus, visual cortex, superior
precuneus, anterior cingulate, dorsal cingulate, gyrus rectus
had significant differences (Sheline et al., 2010). The increase
of amyloid plaques will affect the resting state functional
connectivity of the subjects with normal cognitive before any
abnormal cognition or behavior appear (Sheline et al., 2010).
The influence mechanism of amyloid plaques to resting state
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functional connectivity contributes to the diagnosis of Pre-AD.
In addition, the fMRI study of Theresa M. Harrison et al. also
suggested that altered functional connectivity of hippocampus
was regarded as an important biomarker of Pre-AD (Harrison
et al., 2016).
Alteration of Brain Network via fMRI
With the conversion from normal aging to AD, the functional
networks consisting of different brain regions also are changed.
Therefore, it is valuable to diagnosis of Pre-AD by quantifying
functional networks. Matthew R. Brier et al. introduced graph
theory to detection in change of brain network, which were
regarded as a biomarker (Brier et al., 2014). In addition, they
verified the accuracy of graph theory used to diagnose Pre-AD
by studying the change of cerebrospinal fluid. The results showed
that clustering coefficient decreased and modularity measure
reduced significantly during cognitive decline, and suggested that
large-scale broken connection had existed before the clinical
symptom of Pre-AD appeared (Brier et al., 2014). With the
increasing degeneration of cognitive function, Matthew R. Brier
et al. observed that three important hubs on medial prefrontal
cortices and anterior cingulate lost their own functions gradually
from the phase of CDR 0 to CDR 1, and Pre-AD lay on the
first phase of cognitive deterioration (Brier et al., 2014). In
addition, a few researchers found that medial prefrontal cortex,
bilateral lateral temporal cortex, bilateral parietal/angular cortex,
posterior cingulated cortex/precuneus of normal control also
played the role of hubs (Sepulcre et al., 2010; Drzezga et al., 2011).
Relationship between Brain Imaging via
fMRI and Gene
A few studies suggested that clusterin genotype could affect the
task-based and resting state fMRI paradigms of Pre-AD. The
study of Green AE et al. showed that clusterin genetic risk and
BOLD signals fromMTL during an executive attention task were
negatively correlated (Green et al., 2014). Erk S et al. found
that healthy elder with clusterin had lower coupling strength
between hippocampus and prefrontal cortex during memory
retrieval tasks relative to healthy elder without clusterin (Erk
et al., 2011). These studies implied that there existed modulatory
relationship between BOLD signals and clusterin genotype from
Pre-AD patients (Harrison and Bookheimer, 2016).
In addition, gene also affect functional connectivity between
different brain regions of Pre-AD. The study of Theresa M.
Harrison et al. displayed that healthy elder with ApoE-E4 gene
had lower functional connectivity between anterior hippocampus
and right precuneus, cingulate cortex, anterior insula, also
between anterior hippocampus and posterior hippocampus with
auditory cortex, right precuneus, bilateral supramarginal gyrus
via fMRI on the retrieval phase of paired-associates memory
task (Harrison et al., 2016). Reduction of functional connectivity
between these brain regions can be an important biomarker of
Pre-AD, suggesting that healthy elder with ApoE-E4 gene had a
great risk suffering from Pre-AD.
Problems to be Solved in the Future
In the future, there still exist three problems to be in urgent
need of solution. Firstly, the functional connectivity need to be
quantified, in order to evaluate Pre-AD accurately. In addition,
the analysis methods of functional connectivity via sMRI and
fMRI in the field of MCI require be improved, so that the
improved methods are used to diagnosis of Pre-AD effectively.
Secondly, complex network analysis methods also need be
explored in the future, in order to distinguish Pre-AD from
normal control more accurately at the level of brain network.
Thirdly, considering that the studies about Pre-AD via fMRI
can contribute to locate and find many specific genes, we need
to build the corresponding relation between functional brain
regions and specific genes on the brain model of monkey, and
introduce the relationship to clinical diagnosis of Pre-AD.
CONCLUSION
In conclusion, this paper analyzed in depth recent literatures
related to analysis and diagnosis of Pre-AD from the angle
of biomarkers via sMRI and fMRI. Although current studies
obtained preliminary results, there still existed many problems
to be solved in the future. Especially, it is a valuable angle that
expand current studies from the level of analysis technology.
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